Considerations for successful treatment-free remission in chronic myeloid leukemia Journal Article
| Authors: | Goldberg, S. L.; Savona, M.; Mauro, M. J. |
| Article Title: | Considerations for successful treatment-free remission in chronic myeloid leukemia |
| Abstract: | BCR-ABL1 tyrosine kinase inhibitors have dramatically improved outcomes for patients with chronic myeloid leukemia, and current studies are investigating whether some patients may be able to suspend therapy yet maintain response in a state known as “treatment-free remission” (TFR). Results from ongoing studies suggest that ≈ 40% to 60% of patients in sustained (generally ≥ 2 years) deep molecular response (defined as a 4-log or deeper reduction in BCR-ABL1 transcripts, depending on the study) who attempt TFR may successfully remain off treatment. Results from TFR clinical trials, patient considerations for attempting TFR, and potential predictive factors associated with successful TFR are reviewed herein. © 2017 The Authors |
| Keywords: | cancer chemotherapy; review; drug withdrawal; monitoring; imatinib; dasatinib; chronic myeloid leukemia; prediction; protein tyrosine kinase inhibitor; minimal residual disease; nilotinib; leukemia remission; patient preference; clinical trial (topic); deep molecular response |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 18 |
| Issue: | 2 |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2018-02-01 |
| Start Page: | 98 |
| End Page: | 105 |
| Language: | English |
| DOI: | 10.1016/j.clml.2017.11.006 |
| PROVIDER: | scopus |
| PUBMED: | 29274688 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 March 2018 -- Source: Scopus |
